QIAGEN (QGEN)
(Delayed Data from NYSE)
$46.05 USD
+0.12 (0.26%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $46.04 -0.01 (-0.02%) 6:46 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.05 USD
+0.12 (0.26%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $46.04 -0.01 (-0.02%) 6:46 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Zacks News
Company News For Dec 27, 2019
by Zacks Equity Research
Companies In The News Are: QGEN, IMMU, CANF, SBPH
OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OSMT vs. QGEN: Which Stock Is the Better Value Option?
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
QIAGEN Expands Existing Deal With LabCorp for Better Treatment
by Zacks Equity Research
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
OSMT or QGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OSMT vs. QGEN: Which Stock Is the Better Value Option?
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
by Zacks Equity Research
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%
by Zacks Equity Research
QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View
by Zacks Equity Research
We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.
Qiagen (QGEN) Tops Q3 Earnings Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2.86% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits
by Zacks Equity Research
The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area
QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure
by Zacks Equity Research
If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits
by Zacks Equity Research
QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.
Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
by Zacks Equity Research
Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
by Zacks Equity Research
The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.
QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View
by Zacks Equity Research
QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.
Qiagen (QGEN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
by Zacks Equity Research
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.